The clinical development of tiotropium soft mist inhaler as a new optional therapy for asthma: Positioning of lama for asthma controller

Masakazu Ichinose, Yasunori Suga, Daisuke Kuroki

Research output: Contribution to journalReview articlepeer-review

Abstract

Tiotropium, a long-acting muscarinic antagonist (LAMA), has bronchodilator properties by antagonizing muscarinic receptors in the airway smooth muscle. In Japan, the tiotropium Soft Mist Inhaler (Spiriva® Respimat®) was approved for severe persistent asthma in 2014 and gained approval for asthma with all severity levels in 2016. The UniTinA-asthma® clinical development program, which evaluated the efficacy and safety of tiotropium Soft Mist Inhaler, consisted of 18 clinical trials (phase II, 7 studies; phase III, 11 studies) with over 6000 patients. The phase III UniTinA-asthma® program covered all severity levels of asthma among a broad age range of patients containing children (ages 1-17 years) and adults. In this review, we describe characteristics of tiotropium and each result of phase III studies in UniTinA-asthma® to investigate the efficacy and safety of tiotropium for asthma.

Original languageEnglish
Pages (from-to)1205-1216
Number of pages12
JournalTherapeutic Research
Volume38
Issue number12
Publication statusPublished - 2017

Keywords

  • Asthma
  • Long-acting muscarinic antagonist (LAMA)
  • Respimat
  • Tiotropium

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The clinical development of tiotropium soft mist inhaler as a new optional therapy for asthma: Positioning of lama for asthma controller'. Together they form a unique fingerprint.

Cite this